Insomnia is a sleep disorder in which you have trouble falling and/or staying asleep. The condition can be short-term (acute) or can last a long time (chronic). It may also come and go. Acute insomnia lasts from 1 night to a few weeks. Insomnia is chronic when it happens at least 3 nights a week for 3 months or more.
Wiki Number: W106
US Patients: 20-30%
Sex Ratio: M; W2
Brain Area: sleep apnea; hypothalamic-pituitary-adrenal axis – releases cortisol;higher metabolic rates in PET brain scans; heritability
Symptoms: inability to fall or stay asleep; daytime sleepiness, low energy, depressed mood, dangerous lack fo concentration
Causes: alcohol/benzodiazapine/opioid-induced; changes in sex hormones in elderly
Medications: not recommended for more than five weeks;
Therapies: sleep hygiene = consistent bedtime; quiet and dark room, and regular exercise. CBT; overnight sleep study
4 CURRENT ARTICLES
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Systematic review of productivity loss among healthcare workers due to Covid-19by Maryam Yaghoubi on October 16, 2021
CONCLUSIONS: The early evidence suggests that healthcare workers are one of the most vulnerable groups when it comes to positive COVID-19 infection, mortality, and mental illness.
- Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 studyby F Gernier on October 15, 2021
CONCLUSIONS: VMS and sexual disorders are frequently reported by EOCS, particularly among patients with SM. Most EOCS with menopausal symptoms could benefit from HRT to improve these symptoms.
- Insomnia and poor sleep quality are associated with poor seizure control in patients with epilepsyby A Planas-Ballvé on October 15, 2021
CONCLUSIONS: Sleep disorders are common in patients with epilepsy. Insomnia and poor sleep quality were associated with poor seizure control. These findings support the hypothesis that sleep disorders constitute a significant comorbidity of epilepsy, especially in patients with poor seizure control.
- Pharmacokinetic and pharmacodynamic assessment of histamine H3 receptor occupancy by enerisant: a human PET study with a novel H3 binding ligand, [11C]TASP457by Yasuyuki Kimura on October 15, 2021
CONCLUSION: The target engagement of enerisant was demonstrated in the brains of living human subjects. The occupancy of histamine H(3) receptors by enerisant at 2 h can be predicted by applying the plasma concentration of enerisant to Hill's plot. The preliminary time-course investigation showed persistently high brain occupancy with high doses of enerisant despite the decreasing plasma concentration of the drug. Five milligrams or less dose would be appropriate for the treatment for narcolepsy...